4D Molecular Therapeutics, Inc. Deferred Revenue Recognized
4D Molecular Therapeutics, Inc. (FDMT) reported Deferred Revenue Recognized of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-08.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2025-05-08
- 4D Molecular Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $0.00.
- 4D Molecular Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- 4D Molecular Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was $300.00K, a 75.00% decline year-over-year.
- 4D Molecular Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2022-03-31 was $1.20M, a 7.69% decline year-over-year.
- 4D Molecular Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $700.00K, a 77.42% decline from fiscal 2022.
- 4D Molecular Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was $3.10M, a 79.47% decline from fiscal 2021.
- 4D Molecular Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2021 was $15.10M, a 371.88% increase from fiscal 2020.
- 4D Molecular Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2020 was $3.20M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $700.00K 10-K · filed 2025-02-28 | |||
| 2023-09-30 | $700.00K 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $500.00K 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $300.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $3.10M 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $1.90M 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $1.40M 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $1.20M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $15.10M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $15.10M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $14.00M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $1.30M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $3.20M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $4.00M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $1.60M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |